|
Jul 22
|
Lake Street Sees Big Upside for Aytu Biosciences (AYTU) After EXXUA Acquisition
|
|
Jul 3
|
Aytu Boosts Liquidity with Eclipse Loan Extension
|
|
Jun 25
|
Aytu BioPharma Appoints Dr. Gerwin Westfield as Senior Vice President of Scientific Affairs to Support Commercialization of EXXUA(TM)
|
|
Jun 9
|
Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA(TM) Opportunity and Commercialization Plan
|
|
Jun 9
|
Aytu BioPharma to commercialise Exxua for MDD in the US
|
|
Jun 6
|
Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock
|
|
Jun 6
|
Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA(TM) (gepirone) Extended-Release Tablets in the United States
|
|
Feb 15
|
Loss-Making Aytu BioPharma, Inc. (NASDAQ:AYTU) Set To Breakeven
|
|
Oct 14
|
Aytu BioPharma to Participate in the 2024 Maxim Healthcare Virtual Summit
|
|
Oct 1
|
Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada
|
|
Sep 28
|
Aytu BioPharma Full Year 2024 Earnings: EPS Misses Expectations
|
|
Sep 27
|
Q4 2024 Aytu Biopharma Inc Earnings Call
|
|
Sep 26
|
Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results
|
|
Jun 18
|
Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable Terms
|
|
May 15
|
Aytu BioPharma Reports Fiscal 2024 Third Quarter Operational and Financial Results
|
|
May 8
|
Aytu BioPharma to Report Third Quarter Fiscal 2024 Financial and Operational Results on May 15, 2024
|
|
Apr 3
|
Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024
|
|
Apr 3
|
Presenting on the Emerging Growth Conference 69 Day 2 on April 4 Register Now
|
|
Jan 23
|
Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024
|
|
Jan 16
|
When Will Aytu BioPharma, Inc. (NASDAQ:AYTU) Become Profitable?
|